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Abstract
Investigations of transcript levels on a genomic scale using hybridization-based arrays led to formidable
advances in our understanding of the biology of many human illnesses. At the same time, these investiga-
tions have generated controversy, because of the probabilistic nature of the conclusions, and the surfacing
of noticeable discrepancies between the results of studies addressing the same biological question. In this
article we present simple and effective data analysis and visualization tools for gauging the degree to
which the finding of one study are reproduced by others, and for integrating multiple studies in a single
analysis.
We describe these approaches in the context of studies of breast cancer, and illustrate that it is possible
to identify a substantial, biologically relevant subset of the human genome within which hybridization
results are reproducible. The subset generally varies with the platforms used, the tissues studied, and the
populations being sampled. Despite important differences, it is also possible to develop simple expression
measures that allow comparison across platforms, studies, labs and populations. Important biological
signal is often preserved or enhanced. Cross-study validation and combination of microarray results
requires careful, but not overly complex, statistical thinking, and can become a routine component of
genomic analysis.
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1 Introduction
Microarray experiments measure simultaneously the transcriptional activity of a large number of genes.
In recent years, hundreds of these experiments have been performed, providing important insight on gene
regulation, and revealing some interesting relationships between genes and disease phenotypes. Yet, because
of cost and other practical limitations, most microarray studies have used a relatively small number of
biological samples. As a result, cross-referencing lists of genes found to be associated with disease phenotypes
in two separate studies usually produces relatively few genes in common (Parmigiani et al., 2004), even
when one restricts attention to genes measured in both experiments. While an incomplete overlap is to be
expected given the small samples typically used and the large number of comparisons made, discrepancies
have generated skepticism of this type of investigations.
In this scenario, three related statistical questions are important to making progress towards an objec-
tive assessment of the worthiness of microarray analysis results: 1) reproducibility, that is whether different
measuring techniques are capturing the same biological variation; 2) validation, that is whether the conclu-
sions of a study are supported by other similar studies and 3) combination, that is whether more reliable
conclusions can be reached by jointly analyzing multiple studies. In this paper we develop and illustrate
simple and effective statistical approaches to address these three questions.
Variation in measurements of gene expression includes “technological” variation, associated with lim-
itations of the measuring technologies, and “biological” variation, due to the phenotype or experimental
condition being studied, as well as natural variation of levels of gene expression in different samples of the
same type (Pritchard et al., 2001; Oleksiak et al., 2002; Enard et al., 2002). Because the determinants of
both technological and biological variation tend to vary from study to study and from lab to lab, study- and
lab-specific effects are inherent in most gene expression array datasets. Study-specific conditions may affect
different genes differently, generating study “signatures.” Overall, study effects can dominate the biological
signal of interest (Aach et al., 2000) in a large number of genes.
There are several microarray technologies currently in use (Schena, 2000; Southern, 2001; Hardiman,
2002). Although all exploit hybridization, they differ in how DNA sequences are laid on the array, in the
length of these sequences and in the number of samples measured in each hybridization. As a result, an
important source of technological variability in gene expression measurements is the platform used. Several
studies have compared measurements across platform. Kuo et al. (2002) compared mRNA measurements
from Stanford-type cDNA microarrays and Affy oligonucleotide chips using the so-called “NCI 60” set of
cancer cell lines (Ross et al., 2000; Scherf et al., 2000). Based on correlation between matched measurements
and concordance between clusters, they concluded that correlation can be poor and clusters of genes and cell
lines can be discordant between the two technologies. They also provide evidence to indicate that sequence-
specific factors influence reproducibility. Similar caveats about cross-platform variability have been raised by
other analyses comparing Affy to custom-made cDNA arrays (Yuen et al., 2002) and Affy to IncyteGenomics
arrays (Kothapalli et al., 2002).
To compare experiments that are performed on different gene expression platforms, oligonucleotide probe
sets, spotted sequences, and other microarray features need to be linked. Expressed sequence tag (EST)
sequencing projects have generated cDNA sequences for human, mouse and other organisms. These are
identified by an accession number in databases such as GenBank. Extensive efforts have been devoted to
grouping these sequences into clusters representing a single transcript (Boguski and Schuler, 1995; Miller
et al., 1999; Quackenbush et al., 2001). UniGene, developed at the National Center for Biotechnology
Information (NCBI) (National Center for Biotechnology Information, 2003), partitions ESTs derived from
one organism into mutually exclusive clusters based on sequence homology (Boguski and Schuler, 1995). As
GenBank is growing, UniGene clustering is performed periodically, resulting in new clusters. Typically, a
sequence-specific identifier (GenBank accession number) serves as a reference to the array probe sequences.
A subset of the UniGene clusters is reliably linked to genes of known function such as those catalogues in
LocusLink (National Center for Biotechnology Information, 2004; Pruitt and Maglott, 2001).
Because of these challenges, the first and most critical step in cross-study analysis of gene expression is
to identify a subset of genes that are consistently measured across platforms. Even after two features are
mapped to the same Unigene cluster of LocusLink ID, inconsistencies across platforms can still be substantial
because of differences in hybridization efficiencies, limitations of linkage databases, isoform variation, and a
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number of other factors. To this end, we propose a tool, termed integrative correlation, that can be used
to investigate reproducibility and to isolate a subset of reproducible genes for further analysis. Integrative
correlation was previously illustrated, though not described in any statistical detail, in Parmigiani et al.
(2004) for the two study case. Here we provide a rigorous discussion in the general case of an arbitrary
number of studies, and describe how to choose reproducibility cutoffs using false discovery rates.
We then turn to the assessment of reproducibility of gene selection in class comparison analyses, whose
goal is to identify the genes that are differentially expressed across a given set of conditions or phenotypes. We
propose exploratory analysis techniques based on visualizing suitably chosen standardized effect sizes. Such
visualizations make it simple to place the study-specific effect sizes and their discrepancies across studies in
the context of the variation across the genome. We also build on these visualization to propose simple meta-
analytic methods for selecting genes that are reproducibly associated with a phenotype of interest, and for
assessing the false discovery rates associated with this selection. While typical meta-analytic approaches focus
on combination, our genome-wide implementation focuses on reproducible selection, where reproducibility
is refined both in terms of integrative correlation and consistency of effect sizes.
To illustrate our statistical methods for assessing reproducibility, and comparing results across studies, we
will use three breast cancer datasets (Hedenfalk et al., 2001; Van’t Veer et al., 2002; Huang et al., 2003). Two
of these studies provide information about BRCA1 status of cancers (Hedenfalk et al., 2001; Van’t Veer et al.,
2002) which we will use to determine which genes show evidence of differential expression in BRCA1 and
sporadic breast cancers. BRCA1 positive tumors have shown in some studies to be associated with decreased
survival as compared to sporadic cancers (Foulkes et al., 1997; Robson et al., 2004; Stoppa-Lyonnet et al.,
2000; Moller et al., 2002), while other studies show no association (Verhoog et al., 1998; Pierce et al., 1998).
2 Data
The datasets that we have chosen are three publicly available breast cancer microarray gene expression
studies, of which two had information about BRCA1 status. The first study is by Van’t Veer et al. (2002)
who selected 98 primary breast cancers (18 BRCA1 and 80 sporadic). From each patient, total RNA
was isolated and used to obtain complementary RNA (cRNA). For each sample, two hybridizations were
performed using fluorescent dye reversal on oligonucleotide microarrays containing about 25,000 genes. A
reference pool of cRNA was created by pooling equal amounts of cRNA from each of the sporadic tumor
samples. Intensities were then quantified as log-ratios (as compared to the reference pool), and normalized.
The data from this experiment was downloaded from http://www.nature.com.
The second data was first published by Hedenfalk et al. (2001). Twenty-two breast cancers were analyzed
of which seven are BRCA1 tumors. Complementary DNA (cDNA) was obtained from each tumor sample
and hybridized to two channel cDNA arrays. The reference sample was cell-line MCF-10, a nontumorigenic
breast-cell line. Data from this study was downloaded from http://www.nejm.org, and can also be accessed
at http://www.nhgri.nih.gov/DIR/Microarray.
Huang et al. (2003) analyzed 89 heterogeneous breast tumors which were obtained at biopsy of primary
tumor and banked between 1991 and 2001 and chosen based on clinical parameters. Total RNA was ex-
tracted and synthesized to cDNA. Affymetrix arrays were used for hybridization, arrays were scanned using
Affymetrix GeneArray scanner. We obtained the orignal CEL files from scanned chips and gene expression
was quantified from probe-level information using RMA (Irizarry et al., 2003). BRCA1 information was not
available for this dataset, but we included it in our analysis to demonstrate assessing gene reproducibility
across more than two datasets. The Huang data can be accessed at www.thelancet.com.
Each dataset was preprocessed before being made publicly available.
3 Methods
The methods can be divided into three areas: evaluating reproducibility and reliability of gene expression
across studies, comparing strength of evidence of gene-phenotype associations across studies, and combining
effects across studies. For each dataset, the only genes of interest are the ones which are common across
the studies being compared. For ease of computation, the datasets are hence subsetted to include only the
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common genes based on Unigene ID and are then sorted so that the order of the genes is identical across
studies.
The tools for performing the analyses we demonstrate in this paper are available as an R libary called
MergeMaid (Cope et al., 2004) which can be downloaded at http://astor.som.jhmi.edu/MergeMaid. Func-
tions are available for merging data, estimating correlations within and across studies, performing compar-
ative analyses, and validating gene sets.
3.1 Notation
We use f and h to index studies (i.e., datasets), j and k refer to genes within studies, and nf refers to
the number of samples within study f . The genes which are common across two studies f and h (i.e., the
intersection of genes) is denoted by Gfh whereas Gf is the set of all genes in study f .
3.2 Reproducibility of genes: Integrative correlation
3.2.1 Integrative correlation of two studies
When considering just one gene expression dataset, it can be difficult or impossible to determine whether
or not expression levels are reliably measured. If the spot on the chip is incorrect (i.e. the sequence spotted
does not correspond to the gene that is assumed to be spotted), which is not an uncommon occurence, it
will usually be consistently incorrect for all of the genes in one study because the same type of chips are
generally used within one study. By comparing patterns of expressions across two studies which use different
types of chips (e.g. Affymetrix oligonucleotide chips versus spotted cDNA glass arrays), we may be able to
determine if there are inconsistencies by looking at how the genes are regulated in relation to other genes.
Additionally, if a gene shows relatively little variability across samples, we would expect it to have relatively
low correlations with other genes. To assess which genes lack reproducibility and lack variability, we consider
correlations between genes.
Specifically, gene reproducibility is assessed by looking at the correlation structure across studies. For a
dataset with G genes, the G×G correlation matrix describes how each gene is correlated to every other gene
in the study. If we calculate the correlation matrices for two studies using the same set of G genes and these
datasets both have comparable and reliable gene expression measures across samples, then we would expect
that the two correlation matrices would be similar. In other words, for gene j, the correlation between the
jth row of the correlation matrix in study f and the jth row of the correlation matrix in study h would be
high. We term this the “integrative correlation” for gene j, denoted by rfhj
rfhj =
∑G
g=1,g 6=j(ρfjg − ρ¯fj)(ρhjg − ρ¯hj)√∑G
g=1,g 6=j(ρfjg − ρ¯fj)2
∑G
g=1,g 6=j(ρhjg − ρ¯hj)2
(1)
where ρfjg is the correlation between genes g and j in study f , and ρ¯fj is the average correlation between
gene j and all of the other G genes being assessed. This gene-specific measure can tell us which genes tend to
be measured consistently and with agreement across studies. In general, we do not necessarily expect there
to be high correlations, but we do expect that we will see overall positive trends. Genes showing negative
trends or no trend suggest that the gene signals across the two studies are different for that particular
gene, which may be due to mislabeled spots on the arrays, other chip-specific problems, or artifacts of the
experimental conditions. Genes showing no trend (i.e. correlation close to zero), may lack variability in one
or both studies. Variability can be measured by looking at a gene’s correlation with other genes within the
study: if the variability in the gene is due to signal as opposed to noise, we would expect that the gene would
show a wide range of correlations with other genes. If the range of correlations for a given gene is narrow,
then we conclude that the gene shows little variability. As a result, genes with a narrow range of correlation
with other genes will not be useful in our meta-analysis: the variation in these genes is likely random (i.e.
not related to phenotype) and they will not be helpful is distinguishing between phenotypes.
For any given gene comparison across two studies, we highlight five common scenarios for the resulting
integrative correlation: (1) rfhj is positive and gene j shows variability in both studies f and h, (2) r
fh
j is
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negative and shows variability in both studies f and h, (3) rfhj is low (i.e. close to zero) and variability of
gene j is high in both studies f and h, (4) rfhj shows low correlation and variability of gene j is high in only
one of the studies, and (5) rfhj is low and variability of gene j is low in both studies. These are exhibited
in Figure 1, where the five scenarios are shown via genes 1 through 5, respectively. For each panel, the
correlations of gene j with each of the other genes in Gfh in study f is plotted versus the correlations of gene
j with each of the other genes in Gfh in study h, with the integrative correlations shown for each panel.
Of the five types of genes shown in figure 1, only genes with patterns similar to gene 1 are of interest.
Genes 2 and 3 show different patterns of expression in the two studies, suggesting lack of reproducibility. For
Gene 5, we see low variation in both studies so that the gene is not likely to be informative for distinguishing
between phenotypes. Gene 4 only shows variability in one of the two studies: this suggests that gene 4 could
either be (a) poorly or incorrectly measured in one of the studies, or (b) one of the studies lacks heterogeneity
of samples for gene 4 while the other study shows signficant variability across samples. Regardless of whether
(a) or (b) is true, the gene does not show a comparable pattern across the two studies and cannot be
considered consistently measured. Hence, in addition to identifying genes with inconsistent patterns in the
two studies (i.e. genes like genes 2 and 3), the integrative correlation of genes also identifies genes which do
not show sufficient variability in co-regulation across samples (i.e., like genes 4 and 5). For simplicity, we
refer to genes similar to gene 1 as “reproducible” and genes like genes 2, 3, 4, and 5 as “non-reproducible.”
We consider the integrative correlation a gene’s “reproducibility score.”
Plots like those shown in figure 1 can be made rather easily to see patterns of reproducibility across
datasets. However, Gfh is usually large so that a high throughput method is necessary for determining which
genes are reproducible or not via a cutoff for reproducibility. An attractive approach due to its ease of imple-
mentation and its popularity in gene expression analyses is to use a permutation method. The data within
the rows of the original data matrices are randomly permuted, and the gene-specific correlations recalculated
(i.e. the G×G correlation matrix is recalculated for study f and study h). The reproducibility score based
on the permuted versions of datasets can be used to estimate the null distribution of reproducibility scores:
the scores we would expect to see if the gene expression dataset were based purely on random cross-linkage
of array features. By comparing the null distribution of reproducibility scores to the distribution based on
the original datasets, we can determine a cutoff for reproducibility for which it is expected that only a small
fraction of the genes with scores higher than the cutoff are “false positives” for reproducibility. This is akin
to the false discovery rate (Tusher et al., 2001), but instead of using a cutoff to control the false positive
rate for genes that show differential expression, here we are establishing a cutoff to control the percentage
of genes retained for analysis that are not reproducible across studies. Once the cutoff is chosen, we can
proceed in the analysis using only the genes that have been deemed reproducible.
3.2.2 Integrative correlation of two or more studies
If we are interested in finding out which genes are reproducible across more than two studies, the integrative
correlation as defined above is not directly applicable. As an extension, we consider using an approach based
on the eigenvalues and eigenvectors of the correlation matrices, and using a principal components analysis
approach. Consider first the situation where we are evaluating the reproducibility of gene j in just two
studies and we calculate the correlation between column j in each of correlation matrices of studies f and
h. The two eigenvalues associated with the comparison of these two vectors of correlations are 1 + rfhj and
1 − rfhj , corresponding to the first and second principal components (Johnson and Wichern, 1999; Everitt
and Dunn, 2001). When rfhj > 0, then the 1 + r
fh
j is the eigenvalue associated with the first principal
component, and the second principal component when rfhj < 0. Although it is not obvious by looking at
the two eigenvalues whether or not rfhj > 0, by looking at the signs of the elements in the eigenvector of the
first principal component (i.e. by looking at the “loadings” of the first principal component), we can tell if
the correlation is positive or negative. That is, if the two loadings have opposite signs, then rfhj < 0. So,
instead of calculating the integrative correlation, an equivalent approach would be calculate the eigenvalues,
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Table 1: Comparison of average correlations to λ∗1 for three studies
pairwise correlations
gene 1vs2 1vs3 2vs3 average of correlations λ∗1
A 0.44 0.16 0.32 0.30 0.54
B 0.71 0.05 -0.01 0.25 -0.57
λ1 and λ2, where λ1 > λ2 and the eigenvector of the first principal component is {a11, a12}. We then define
λ∗1 = λ1/2 if a11 × a12 > 0
= −λ1/2 if a11 × a12 < 0.
In the above equation, the integrative correlation rfhj and λ
∗
1 are equivalent. Additionally, we can use a
permutation approach as described in the previous section to estimate the null distribution of λ∗1 and we
obtain the same set of reproducible genes.
Using the eigenvalue approach, we can now extend integrative correlation to three studies. Recall that
in a principal components analysis of k variables, the sum of the eigenvalues
∑
λi = k, and λi/k is the
proportion of variability in data that is described by the ith principal component. As such, if the eigenvalue
of the first principal component is high, it indicates that there is a strong linear relationship for gene j
across all three studies. Note, however, that the eigenvalue does not distinguish between the direction of the
associations: it could be that two studies have strong agreement for gene j and the third study has strong
by negative correlation of gene j with the other two studies. In that case, the eigenvalue would be large
but the gene is not reproducible across the three studies. However, just as we can use information in the
eigenvectors in the case of two studies, we can use an analogous approach for k = 3 study comparisons:
λ∗1 = λ1/3 if a11 × a12 > 0 and a11 ∗ a13 > 0
= −λ1/3 if a11 × a12 < 0 or a11 ∗ a13 < 0.
Note that the λ∗1 statistic takes the same range as a correlation and has a similar interpretation. In the above
equation, only if all three components of the first eigenvector have the same sign will λ∗1 have a positive sign.
Similarly, a permutation distribution can be determined as above but in this case all three studies are required
to be randomly permuted before re-analyzing the data. The principal components approach can clearly be
extended to assess reproducibility between any number of studies.
The above approach is similar, yet superior to estimating the pairwise integrative correlation between
each pair of studies and averaging the pairwise correlations. In table 1, there are two different correlation
scenarios that produce similar average correlations, but quite different values of λ∗1. Gene A shows moderate
correlation across the three studies, resulting in an average correlation of 0.30 and a value of λ∗1 of 0.54.
For gene B, it appears that the gene is measured consistently in two of the studies, with a high correlation
between two studies of 0.71, but the gene is poorly measured in study 3, with correlations between studies
1 and 3 of -0.05 and between studies 2 and 3 of -0.01. For gene B, the average correlation is 0.25, while
λ∗1 = −0.57. So, if using the average correlation, we cannot distinguish between the types of correlation
patterns in genes A and B, while there is a very distinct difference in λ∗1.
Depending on the ultimate goal of these analyses, the λ∗1 value can be used for different purposes. Using a
permutation approach, we can identify all genes which show agreement above that which would be expected
due to chance. Specifically, we randomly permute the gene expression values (by gene) in the three studies
and repeat the estimation of λ∗1 using the now permuted datasets. We can then compare the empirical
distribution of λ∗1 based on the permuted and non-permuted datasets. Some cutoff sα is chosen to control
the rate of unreproducible genes included in the analysis. In the example shown in table 1, gene A would
likely be chosen as reproducible while gene B would not.
Note that the range of values of λ∗1 can also be used for identifying genes which show strong evidence
of poor measurement in one of the studies. Genes with large negative values of λ∗1 such as gene B clearly
show some agreement (in gene B, there is strong agreement between studies 1 and 2), but the negative sign
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indicates that one study does not agree with the other studies. So, comparing the pairwise correlation values
(i.e. the integrative correlation based on just two studies) to λ∗1 is helpful for determining which genes appear
to be poorly measured within each study. This can be a very useful result for future analyses of the datasets
under investigation.
3.3 Comparative Analyses
3.4 Binary Phenotypes
After choosing genes to include in the analysis based on their reproducibility, the association between gene
and phenotype can be compared across two studies. First, however, summary statistics need to be calculated
in each study, quantifying the association between gene and phenotype for each of the reproducible genes.
We find this preferable to combining the raw data values across studies. In our experience, gene expression
data cannot be easily combined just as in many meta-analysis settings. A few reasons for this include that
often times the available data has been preprocessed using algorithms so that the original data cannot be
recovered (as is the case with the Vant’ Veer data in our study), the experimental designs of the studies
including sample selection may be different, and the measurement of expression might be different (e.g.
log-ratio of expression versus absolute expression). Others have integrated datasets, but using studies with
comparable chip measurement (Jiang et al., 2004; Shedden and Taylor, 2004; Morris et al., 2004) unlike our
situation.
In the case of a binary phenotype variable, we can detect which genes are associated with phenotype in
several ways. Logistic regression can be used, where phenotype is regressed on gene expression for each gene,
and the log odds ratio quantifies the relationship. While naturally appealing, because this model implies
that gene expression is “predictive” of phenotype, this approach runs into problems when gene expression
perfectly predicts phenotype. That is, when there exists a gene whose range of expressions for the two
phenotypes do not overlap, the odds ratio is not estimable using a standard logistic regression approach.
As an alternative, a difference in means and a t-ratio approach can be used, where the average expression
in the two phenotypes are compared. To provide a common metric across studies, for each gene in each study,
we divide the gene expression data by the standard deviation of gene expression data in the reference type
before estimating the difference in means (e.g., in the BRCA1 versus sporadic example, we would consider
sporadic as our reference phenotype). This transforms the data so that, regardless of platform, effect sizes
are comparable across studies, representing the number of standard deviation units that the two phenotypes
differ per gene. As a result, our effect size, wj , for gene j is measured by the differences in the means in the
two groups being compared, divided by the standard deviation of the reference group:
wj =
x¯2j − x¯1j
SD1j
. (2)
We use the wj value to tell us about the “effect size” for the association between phenotype and gene
expression for gene j.
In addition to looking at effect sizes, to assess statistical significance of the observed differences in
expression across the two groups, we can use a significance analysis of microarrays (SAM) approach, an
extenstion of the t-test. The SAM statistic (dj) is calculated for each gene j making an adjustment for
variance stabilization (Tusher et al., 2001). Note that there are many different statistics that can be chosen:
we have used the SAM statistic for illustration. The SAM statistic (dj) has been widely used for detecting
differentially expressed genes in gene expression microarray studies and takes the form
dj =
x¯2j − x¯1j
sj + s0
(3)
where the standardized mean expression in the two phenotypes for gene j are denoted by x¯1j and x¯2j , and sj
is a pooled estimate of the standard error of the difference. The way in which dj differs from the t-statistic
is the inclusion of s0, which is chosen to minimize the coefficient of variation of dj , where the coefficient of
variation of dj is computed as a function of sj in moving windows across the range of sj . When the t-ratio is
used in gene expression analyses, many genes tend to be deemed significant that have very small variation in
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expression across phenotype, but also have small standard errors. The SAM statistic adjusts for that with
the addition of s0 in the denominator, picking up more genes with larger effect sizes and fewer genes with
inconsequential differences.
Notice the difference between wj and dj : wj is simply a scaled version of the effect size (similar to a
standardized regression coefficient), while dj is more comparable to a t-statistic, which directly provides
information about statistical significance. The major computational difference is that dj is sample size
adjusted because it uses a standard error in the denominator, whereas wj is not sample size adjusted, using
a standard deviation in the denominator. One reason to prefer wj to dj is that when considering studies
of different sizes, the values of dj are not directly comparable while the wj statistics are. After these
computations have been made for each of the reproducible genes in each of the studies, we can compare the
results using simple scatterplots, including statistical significance (determined by SAM or another approach)
as part of the display.
3.5 Survival and Continuous Phenotypes
In many of the oncologic gene expression data that are collected, time to death or relapse is of primary
interest. Researchers are intent on finding genes which may be predictive of good or poor prognosis. The
approach used above for comparing results for binary phenotypes can be extended. Just as the logistic
regression approach was mentioned for looking at binary phenotypes, a Cox proportional hazards model
approach can be used for assessing associations between time to death and gene expression, where survival
time or relapse time is regressed on gene expression. Unlike the estimation problem that may occur in logistic
models, the Cox model will accomodate any gene expression data that shows some variation across samples
and has at least several failures.
Log hazard ratios and their statistical significance can be compared across studies. However, the data
needs to be standardized first in order that the units of the log hazard ratios are comparable. A logical
approach is to subtract the row mean (or median) and then divide by the row standard deviation (or
another measure of variability) for each row of the gene expression matrix. Additionally, we can use the
SAM-type adjustment: we can find the log hazard ratio (hj) and its standard error (sj) for each gene, to
calculate the Z-score (Zj = hj/sj) for each gene. Then we can estimate the value of s0 that stabilizes the
variability of the Z-scores and recalculate the Z-score such that
Zj =
hj
sj + s0
. (4)
The SAM approach as applied to Cox regression coefficients was used by Bullinger et al. (2004) for finding
gene expression profiles associated with survival in acute myeloid leukemia patients.
Continuous outcomes can be handled analogously, using linear regression where continuous phenotype is
regressed on (standardized) gene expression for each gene. In the case of linear regression, it is suggested
that some time be spent ensuring that a linear model is appropriate: by studying the linear regression model
on several randomly chosen genes and several genes which show strong association with phenotype, the
assumptions of linearity and constant variance can be explored.
3.6 Displaying Results Comparing Effect Sizes Across Studies
An intuitive way to look at the agreement between effect sizes for many genes across studies is to create
a scatterplot, with effect sizes for one study on the x-axis and for the other study on the y-axis. Instead
of plotting a least squares regression line (i.e. a “best-fit” line determined by minimizing the sum of the
squared vertical residuals), we advocate plotting the best-fit line that is found by minimizing the sum of the
squared perpendicular residuals. This line can be found by estimating the first principal component ({a1, a2})
associated with the covariance between the effect sizes. The best-fit line has slope a2a1 and intersects the point
of the mean effect size of both studies. This line is more appropriate than a linear regression line because it
is invariant to which study is plotted on the x-axis and which on the y-axis unlike the least squares line.
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3.7 Combining Estimates Across Studies
The techniques we propose can generally be considered meta-analytic approaches to analyzing gene expression
data. Meta-analysis is a broad area consisting of techniques for analyzing data obtained from different studies.
In our methods, we do not actually combine the data across studies, but instead perform comparative
analyses, making inferences based on consistency across studies, and estimate combined inferential statistics.
A clear understanding of the basic tenets of meta-analysis are critical to make logicial comparisons. General
reviews of meta-analysis include Normand (1999); Hedges and Olkin (1985); Cook et al. (1995). Ghosh et al.
(2003); Moreau et al. (2003) provide discussions of some of the statistical issues that arise when performing
meta-analysis in gene expression arrays, including combining measures from different platforms, complex
data structures, multiple comparisons, and duplicate spots within arrays.
Just as in standard meta-analytic approaches, we can go one step further and estimate “pooled” estimates
of effect sizes. For example, when looking at overall survival, we could estimate a pooled hazard ratio estimate
across studies for each gene in common across a set of studies. Variation in estimates might be assumed to
arise from a fixed effects models, such that, for each gene, the log hazard ratios across studies are realizations
from a large population of estimates with a common mean, θj . On the other hand, a random effects approach
could be assumed, where for each gene and each study, we assume a different mean (e.g. θfj). The latter
is a more reasonable approach in general for combining the results from gene expression array experiments
due to the many sources of heterogeneity across studies, including the variety of tissues and differences in
experimental methods.
However, in the gene microarray setting, we are often in the situation of comparing the results of just a
few studies. In our applied example, we have only two microarry studies of breast cancer with information on
BRCA1 status. As a result, a random effects approach is not feasible and alternative methods for combining
effects need to be utilized. We outline an approach for combining effects across two studies which can be
extended for k > 2 studies. For k >> 2, we recommend considering a random effects approach as described
above.
To combine results, consider first the situation where the studies to be combined have equal sample sizes
and the average effect size in each study is 0. In this case, one logical approach would be to simply average
the effect sizes in the two studies. Another approach would be to use the best-fit line defined in the previous
section, project each point to the best-fit line, and use the distance from the origin to the projected point
(divided by
√
2 to preserve the metric) to represent the combined effect size. Using the definitions of a1 and
a2 from the section 3.6, to combine effect size w1 from study 1 and w2 from study 2, we would estimate the
combined effect wc as wc = a1w1+a2w2a1+a2 . This is analogous to using the “fitted” value from linear regression as
a best estimate of y for a given value of x. A major difference with this approach is that x and y are treated
symmetrically, unlike a linear regression approach. In linear regression, a horizontal line (with slope=0)
indicates no linear association between x and y. When using our approach, with the line fitted based on
perpendicular residuals, either a horizontal line with slope of 0 or a vertical line with slope of ∞ indicate no
linear association between x and y.
In practice, we need to make some modifications to the above approach because (a) sample sizes are
generally not the same and we would like to give more weight to estimates from studies with larger sample
sizes, and (b) the average effect size in each study is generally not equal to zero (although they are often
very close to zero). Our method for combining results across two studies is described in box 1 below:
1 Define the two vectors w1 and w2 to be the vectors representing effect sizes in the two studies.
2 Center w1 and w2 by their means.
3 Fit principal components to w1 and w2 using covariance, saving a1 and a2, the loadings of the first
principal component.
4 Estimate the combined effect: wc =
a1
√
n1w1+a2
√
(n2)w2
a1
√
n1+a2
√
n2
.
Step 2 ensures that the fitted line intersects the origin. Step 3 uses covariance (instead of correlation)
which uses variation in estimates to determine which study should be weighted more heavily: studies with
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more variation in estimates will tend to be favored. Step 4 does two things: (a) it sample size adjusts the
fitted line, and (b) it rescales the metric to preserve the original scale of the effect sizes.
The vector wc can now be used for determining which genes are associated with phenotype using the
combination of information from the two studies. This can be done using a permutation approach: for each
study, the gene expression data is randomly permuted by row, effect sizes are recalculated, and the combined
estimates are then recalculated. The distribution of combined effect sizes is compared to the combined effect
sizes based on the the permutation approach.
4 Results
The three studies described in section 2 (referred to as Hedenfalk, Huang, and vant’ Veer) were analyzed for
reproducibility, and we assessed the comparability of results of the Hedenfalk and vant’ Veer in regards to
the genes associated with BRCA1 status.
4.1 Merging datasets
The bioconductor library MergeMaid was used for merging the three datasets. The MergeMaid library
combines phenotype and gene expression data from multiple studies, averages multiple occurences of genes
within a study before merging, keeps track of which genes are in common across studies, and sorts genes
consistently across studies. We found that the Hedenfalk and vant’ Veer study had 1121 genes in common,
Hedenfalk and Huang had 1668 in common, and vant’ Veer and Huang had 5108 in common. Across all
three studies, there were 941 common genes.
4.2 Reproducibility
Reproducibility was assessed for each pair of studies by calculating the pairwise and the overall integrative
correlations. The distributions of the pairwise integrative correlations and their null distributions (as deter-
mined by permutation) are shown in figures 2A, 2B, and 2C. The sα cutoff was set to 1%, meaning that 1%
of genes deemed reproducible will not be reproducible. We can see the effect that sample size has on these
null distributions: the null integrative distribution for the Huang (n=89) vs. vant’ Veer (n=98) study is
very narrow as compared to the null distributions involving the Hedenfalk study (n=22). From these plots,
approximately 80% of the genes are reproducible between vant’ Veer and Huang, 60% between vant’ Veer
and Hedenfalk, and 60% between Huang and Hedenfalk.
The overall integrative correlation (i.e. λ∗1) is shown in figure 2D. Notice a small bump in both distribu-
tions to the left of the mode. This can be explained as representing genes that have high correlation between
two of the three studies, but are such that the third study has negative correlation with the other two
studies. In these cases, it is likely that the gene is incorrectly measured in the discordant study. The overall
integrative correlation for the three studies is less conservative than the pairwise integrative correlations:
approximately 85% of genes are defined as reproducible (797 of the 941 common genes). Note that in figure
2D, there is flattening of the null distribution at a value for the integrative correlation of 0. This is due to
the nature of the principal components analysis. With three variables included in the analysis, the chance
that the pairwise correlations between all three variables is zero is virtually zero. As such, the probability
of obtaining an integrative correlation of 0 when more than two studies are being compared is essentially 0.
In Figure 3, we compare the behavior of the overall integrative correlation (λ∗1) with the average of the
pairwise correlations. For both λ∗1 and the average pairwise correlations, permutation test were performed,
where gene reproducibility was defined by the upper 5% of the null distribution. That is, any gene with
reproducibility scores larger than the 95th quantile of the null distribution is considered to be reproducible.
Note that this cutoff is somewhat arbitrary–other cutoffs can be chosen depending on user preference. The
integrative correlation is shown on the x-axis, the average pairwise correlation on the y-axis, and the points
are coded to identify which genes are deemed reproducible by each method. Notice the linearity in the
upper right of the figure. However, in the upper and lower left, there are marked departures from linearity.
Overall, there is good agreement: the majority of the genes are blue (reproducible by both methods), or green
(unreproducible by both methods). In this analysis, there are no genes which are found to be reproducible
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by integrative correlation but not by the average correlation , but there are a handful of genes (shown in
red) which are reproducible by the average correlation but not by the integrative correlation, λ∗1. These are
the genes that we saw in the little bump in figure 2D: they are genes which agree strongly in two studies,
but not in the third. Genes such as these are interesting because they should be considered in any pairwise
comparisons between the studies in agreement. However, when trying to obtain genes which are consistently
measured in all three studies, these genes show relatively strong evidence of discordance.
4.3 Comparing and combining gene associations for BRCA1
In order to investigate the comparability of results across the Hedenfalk and vant’ Veer studies, we restrict
our attention to genes which were determined to be reproducible across the two studies, as defined above.
For each of the two studies, effect sizes, wj , are estimated for the reproducible genes and plotted versus
each other, with the best-fit line included, plotted using a solid line (figure 4A). Recall that the best fit line
is determined by minimizing the sum of the squared perpendicular residuals and its interpretation should
not be confused with the interpretation of the standard least squares regression line. In this case, the slope
represents the ratio of variability explained by the variable measured on the y-axis as compared to the one on
the x-axis. Hence, a slope of 0 or∞ means that there is no association between the effects in the two studies.
In figure 4A, the slope is close to 1, suggesting comparable explanatory power for the two studies. As a
contrast, the effect sizes and the best fit line (in solid) is shown for the unreproducible genes in figure 4B,
which is close to vertical, suggesting almost no association between the two studies among the unreproducible
genes.
The dotted lines on figures 4A and 4B represent the sample size adjusted combined effect size. Notice
that both of these are shifted downward toward the x-axis, favoring the estimates in the vant’ Veer study.
We next combined scores, weighting by the principal components loadings and study sample sizes, as
described in box 1. The distribution of combined effect sizes is shown in figure 5, along with its null
distribution. Genes were considered significantly associated with BRCA1 status if they were beyond the
2.5th or the 97.5th percentile of the null distribution. Out of the XXX reproducible genes analyzed, a total
of 226 genes were found to be significantly associated with BRCA1 using the combined results of the two
studies. An additional quantity of interest is the combined dj value, which is essentially the SAM statistic
averaged across studies. This is shown as compared with our combined effect size in figure 6. As can be
clearly seen, these two statistics are highly correlated, although the ranges are rather different due to the
sample size adjustment in dj .
5 Discussion
Given the multitude of gene expression studies that are currently available, it is clearly of interest to make
inferences based on their collective evidence. Additionally, given the concerns that gene expression data is
often poorly reproducible, it is important to be able to confirm results found in one study by looking at other
similar studies. When looking at a single study, we usually do not have the ability to statistically evaluate
the reliability of gene measurement and instead usually rely on gene-by-gene validations using methods such
as RT-PCR among a small subset of genes found to be interesting. When multiple studies are available,
statistical cross-study validation offers an effective, high-throughput alternative that should be exploited
more routinely in genomic analyses.
In this article we describe simple tools for both the comparison of results and the combination of asso-
ciation measures across two or more studies. We focused on studies of gene expression using micorarrays,
because they are common, expensive, and controversy exists on their validity. Our analysis plans can be ex-
tended to other high throughput techniques for measuring the transcriptome and the proteome. We focused
on class comparison issues, though reproducibility filters would be advisable in class prediction and class
discovery settings as well.
In practice, we suggest that reproducibility should always be considered before comparing results across
studies. By filtering out genes that appear to be mismeasured or incorrectly linked, we avoid making
comparisons that are not biologically relevant, and we will likely substantially reduce both the number of
discordant findings and the number of falsely concordant findings. This allows us, to some extent, to separate
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the technology-specific and study-specific variation from the biological variation: for example, while strong
biological variation can lead to small integrative correlations, it is far less likely to lead to negative integrative
correlations. The latter are more likely the result of inaccurate cross-linkage or strong differences in the
hybridization behavior of the sequences used as probes in different platforms.
A novel addition in this paper is the extension of the reproducibility assessment to more than two
studies. In the case of two studies, calculating a measure to describe the overall agreement between two
studies is straightforward. However, when looking at more than two studies, finding a one-number summary
of the overall agreement led us to principal components analysis, and a statistic based on the value of the
eigenvalue associated with the first principal component, with sign based on the signs of the elements of the
eigenvector. In practice, this approach has been useful for finding genes which are measured consistently
across all studies and also for finding genes which are measured consistently in only two of three studies,
suggesting mismeasurement in the third study.
While individual studies may not provide convincing evidence of gene-phenotype relationships, collectively
analyzing gene expression datasets with the same phenotypes may provide substantially more information.
By looking at a collection of datasets, we can assess which genes appear to be reproducible across studies
and which show consistent trends in their association with phenotype. Many gene expression datasets are
publicly available so that now there are collections of datasets, each with the goal of finding associations
between phenotype and genes.
To date, while many authors have compared platforms using the same samples in controlled experiments
(Kuo et al., 2002; Yuen et al., 2002; Barczak et al., 2003; Culhane et al., 2003; Mecham et al., 2004; Kothapalli
et al., 2002) there have been few researchers who have published approaches for combining information
across samples and platforms from different studies. Grigoryev et al. (2004) combined gene expression
across different Affymetrix chip types (U47A, U34A, U95A, and U133A) for different animal species. Their
approach included matching genes using orthologs (i.e. matching genes across species) and directly combining
normalized gene expression data before analysis to obtain overall measures of “statistical significance” of
orthologs. While this may be an appropriate method across matched Affymetrix chip technologies, the
applicability of this approach for different platforms is unlikely. Rhodes et al. (2002) meta-analyzed four
prostate cancer gene expression studies, comparing prostate tumor tissue to benign prostate tissue. For each
gene, they first computed the p-value to the test for the null hypothesis of no difference across the two groups.
They then ranked these p-values within each study and combined the resulting ranks. Combining p-values
according to their ranks is consistent in this case with combining t-statistics according to their ranks. Test
statistics and their significance values depend both on information about the magnitude of the fold-change
across the two classes considered, and on information about the precision with which this fold change can
be measured in the experiment at hand. The latter reflects within-class variability for a gene, but also the
study sample size. Therefore, it would not have been appropriate to combine p-values or t-statistics directly
across studies (although their rank can be combined). Because of this limitation, most of the combination
approaches developed in medicine (Hedges and Olkin, 1985; Hasselblad and McCrory, 1995) are based on
standardized effects (SE). In the genomic context a SE for a two-class comparison could be defined as the
fold-change divided by the within-class standard deviation. SEs have the added advantage of allowing for
direct combination across studies. This approach is likely to use information more efficiently and also leads
to a combined estimate of direct biological interpretation.
Using the approaches that we have developed for comparing the two studies that include BRCA1 infor-
mation, we were able to show that, in general for the reproducible genes, there was quite good agreeement in
terms of magnitude and direction of the associations between genes and BRCA1. And, the results seen for
the non-reproducible genes make sense: they have a correlation close to zero. Had these genes been left in
the analysis, we would have dampened the estimated association between effect sizes in the two studies. We
chose to use the effect size, defined as the difference in mean expression between the BRCA1 and sporadic
samples, standardized by the standard deviation in the sporadic samples. However, there are many possible
choices for statistics of interest to be compared. SAM statistics can be compared, although the magnitude
across studies might vary significantly due to differences in sample sizes.
The R library MergeMaid has been developed for performing the analyses that we present, including
matching datasets, assessing reproducibility of genes, and performing comparative analyses across datasets
and can be accessed freely from http://astor.som.jhmi.edu/MergeMaid. These tools can be applied
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generally to datasets from any gene expression platforms for which there exist a set of overlapping genes.
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Figure 1: Examples of correlations between correlations of genes.
16
http://biostats.bepress.com/jhubiostat/paper65
−0.4 −0.2 0.0 0.2 0.4 0.6
0
5
1 0
1 5
2 0
2 5
(A) Vant’Veer and Huang
Integrative Corr
D
e n
s i
t y
−0.4 −0.2 0.0 0.2 0.4 0.6
0
2
4
6
8
1 0
1 2
(B) Vant’Veer and Hedenfalk
Integrative Corr
D
e n
s i
t y
−0.2 0.0 0.2 0.4
0
5
1 0
1 5
(C) Huang and Hedenfalk
Integrative Corr
D
e n
s i
t y
−0.4 −0.2 0.0 0.2 0.4 0.6
0
5
1 0
1 5
2 0
(D) Vant’Veer, Huang, and Hedenfalk
Integrative Corr
D
e n
s i
t y
Figure 2: Distribution of integrative correlations across studies. (A) vant’ Veer and Huang, (B) vant’ Veer
and Hedenfalk, (C) Huang and Hedenfalk, (D) All three studies.
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Figure 3: Comparison of using the integrative correlation based on principal components approach (x-
axis) and the average of the pairwise correlations (y-axis). Blue points are deemed reproducible by both
approaches, green points non-reproducible by both approaches, and red points as reproducible by the average
of pairwise correlations but not by the principal components based integrative correlation.
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Figure 4: Scatterplots of effect sizes in two studies. Solid line represents the best fit line based on perpen-
dicular residuals. Dotted line is the sample size adjusted line (which favors vant’ Veer which is the larger
study). Recall that perfectly vertical or horizontal lines indicate no correlation. (A) Reproducible genes, (B)
Unreproducible genes.
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Figure 5: Distribution of combined effect sizes and the null distribution of effect sizes.
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Figure 6: Scatterplot of the combined effect size versus the combined SAM statistic.
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